

## H1N1 Vaccines Market Growth, Upcoming Trends, Companies Share, Structure and Regional Analysis by 2022-2027

Looking forward, IMARC Group expects the market to reach US\$ 4.6 Billion by 2027, exhibiting at a CAGR of 5.4 % during 2022-2027.

STE R SHERIDAN, WYOMING, UNITED STATES, April 25, 2022 /EINPresswire.com/ -- According to IMARC Group's latest report, titled "H1N1 Vaccines Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027", the global market reached a value of US\$ 3.4 Billion in 2021. H1N1 refers to a subtype of the Influenza A virus that causes an infectious disease characterized by a persistent cough,



H1N1 Vaccines Market Report

high fever, red and watery eyes, body ache, headache, etc. It is known to have a detrimental effect on various existing chronic ailments, including pneumonia, Chronic Obstructive Pulmonary Disease (COPD), bronchitis, etc. H1N1 vaccines are a preventive measure taken through intradermal and intranasal procedures to offer active immunization against the virus.

Request for a PDF sample of this report: <a href="https://www.imarcgroup.com/h1n1-vaccines-market/requestsample">https://www.imarcgroup.com/h1n1-vaccines-market/requestsample</a>

The rising incidences of H1N1 infection and the declining immunity of the general population against the virus are primarily driving the H1N1 vaccines market. Besides this, the expanding geriatric population across the globe is also bolstering the market growth since, with age, the risk of developing respiratory tract diseases and immunodeficiency disorders rises, making individuals more susceptible to the H1N1 virus. Additionally, the elevating levels of R&D activities in the field of immunology and vaccine technologies are also augmenting the global market. Apart from this, numerous developed countries, such as Australia and the United States, are adding H1N1 vaccines under their National Immunization Program (NIP), which is further

propelling the product demand. Moreover, continuous technological advancements, coupled with the increasing awareness towards preventive methods, are expected to fuel the H1N1 vaccines market over the forecasted period. Looking forward, IMARC Group expects the market to reach US\$ 4.6 Billion by 2027, exhibiting at a CAGR of 5.4 % during 2022-2027.

Checkout Now: <a href="https://www.imarcgroup.com/checkout?id=1314&method=1">https://www.imarcgroup.com/checkout?id=1314&method=1</a>

As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviors of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

impact of this pandemic.
Market Segmentation:
Breakup by Vaccine Type
Intramuscular Intranasal Intradermal
Breakup by Market Type:
Public Private
Analysis of Key Brands:
Agripal Fiuarix
Influgen
Influvac
Nasovac

Breakup by Region:

Vaxigrip Others

North America
Europe
Asia Pacific
Middle East and Africa
Latin America

Ask Analyst for Customization and Explore full report with TOC & List of

Figures: <a href="https://www.imarcgroup.com/h1n1-vaccines-market">https://www.imarcgroup.com/h1n1-vaccines-market</a>

Note: We are updating our reports, If you want the report with the latest primary and secondary data (2022-2027) including industry trends, market size and Competitive landscape, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours.

Key highlights of the report:

Market Performance (2016-2021)
Market Outlook (2022-2027)
Market Trends
Market Drivers and Success Factors
Impact of COVID-19
Value Chain Analysis
Comprehensive mapping of the competitive landscape

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

Related Reports by IMARC Group:

East Africa Generic Drug Market: <a href="https://www.imarcgroup.com/east-africa-generic-drug-market">https://www.imarcgroup.com/east-africa-generic-drug-market</a>

Europe Generic Drug Market: <a href="https://www.imarcgroup.com/europe-generic-drug-market">https://www.imarcgroup.com/europe-generic-drug-market</a>

India Minimally Invasive Surgery Market: <a href="https://www.imarcgroup.com/india-minimally-invasive-surgery-market">https://www.imarcgroup.com/india-minimally-invasive-surgery-market</a>

Europe Transfection Technologies Market: <a href="https://www.imarcgroup.com/europe-transfection-technologies-market">https://www.imarcgroup.com/europe-transfection-technologies-market</a>

Vein Illumination Devices Market: <a href="https://www.imarcgroup.com/vein-illumination-devices-market">https://www.imarcgroup.com/vein-illumination-devices-market</a>

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

Elena Anderson IMARC Services Private Limited +1 6317911145 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/569830079

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2022 IPD Group, Inc. All Right Reserved.